Clinical Trial

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832. The study is conducted in 2 parts: Part 1 assesses the potential effect of the CYP3A inhibitor itraconazole on the metabolism of OPC-167832 and Part 2 assesses the potential effect of the CYP3A inducer carbamazepine on the metabolism of OPC-167832 in healthy adult participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-14.
Trial Details
NCT Number NCT07542847
Lead Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions Healthy Volunteers
Enrollment 24 participants
Start Date 2022-09-19
Primary Completion 2022-11-18 (estimated)
Study Completion 2022-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-05